FLT3 and acute myeloid leukemia: Numerous studies have demonstrated the synergistic effect in AML of Vorinostat in combination with other compounds, such as the aurora kinase inhibitor MK-0457 [69], the proteosome inhibitor NPI-0052 [70], cytosine arabinoside (also known as Cytarabine), Etoposide [71], the BH3-mimetic GX15-070 [72], the Wee1 inhibitor AZD1775 [73], or the FLT3 inhibitor BPR1J-340 [74], among others.